QQ客服 官方微博 反馈留言

浏览/检索结果: 共13条，第1-10条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials 期刊论文 2019, 卷号: 93, 期号: ,SI, 页码: 832-838 作者:  Xu, Kai;  Fu, Guosheng;  Xu, Bo;  Zhou, Yujie;  Su, Xi 收藏  |  浏览/下载：14/0  |  提交时间：2020/01/03 bioresorbable scaffold  coronary artery diseases  objective performance criterion  percutaneous coronary intervention  sirolimus-eluting stents   Primary endpoint Outcomes of A Prospective, Single-Blinded, Multi-Center, Randomized, Controlled, Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent (R) System) compared to TIVOLI in the Treatment of Patients with Coron 期刊论文 2018, 卷号: 72, 期号: 16, 页码: C120-C120 作者:  Han, Yaling;  Wang, Zhiyong;  Pei, Hanjun;  Zhang, Li;  Yang, Yuejin 收藏  |  浏览/下载：13/0  |  提交时间：2020/01/03 Primary endpoint Outcomes of A Prospective, Single-Blinded, Multi-Center, Randomized, Controlled, Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent (R) System) compared to TIVOLI in the Treatment of Patients with Coron 会议论文 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018-10-16 作者:  Han, Yaling;  Wang, Zhiyong;  Pei, Hanjun;  Zhang, Li;  Yang, Yuejin 收藏  |  浏览/下载：9/0  |  提交时间：2020/01/03 The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer 期刊论文 2018, 卷号: 22, 期号: 2, 页码: 1257-1271 作者:  Shao, Bianfei;  Feng, Yixiao;  Zhang, Hongbin;  Yu, Fang;  Li, Qianqian 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03 ADAMTS9  tumour suppressor  methylation  EGFR  TGF beta   A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents 期刊论文 2018, 卷号: 11, 期号: 3, 页码: 260-272 作者:  Han Yaling;  Xu Bo;  Fu Guosheng;  Wang Xiaozeng;  Xu Kai 收藏  |  浏览/下载：11/0  |  提交时间：2020/01/03 bioresorbable scaffolds  drug-eluting stent(s)  randomized controlled trial   Evaluation of the therapeutic effects of QuickOpt optimization in Chinese patients with chronic heart failure treated by cardiac resynchronization 期刊论文 2018, 卷号: 8, 期号: 1, 页码: 4259 作者:  Yan, Ji;  Zhang, Shu;  Huang, Dejia;  Xue, Xiaolin;  Xu, Jing 收藏  |  浏览/下载：11/0  |  提交时间：2020/01/03 Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis The RESTORE ISR China Randomized Trial 期刊论文 2018, 卷号: 11, 期号: 23, 页码: 2368-2377 作者:  Chen, Yundai;  Gao, Lei;  Qin, Qin;  Chen, Shaoliang;  Zhang, Jun 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03 drug-coated balloon  drug-eluting stent(s)  in-segment late loss  in-stent restenosis   Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Shao Zhimin;  Li, Junjie;  Pang, Da;  Wang, Changqing;  Jiang, Jun 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Shao Zhimin;  Li, Junjie;  Pang, Da;  Wang, Changqing;  Jiang, Jun 收藏  |  浏览/下载：10/0  |  提交时间：2020/01/04 Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial 期刊论文 2016, 卷号: 12, 期号: 10, 页码: 1279-1287 作者:  Zhang, Yao-Jun;  Wang, Xiao-Zeng;  Fu, Guosheng;  Jing, Quan-Min;  Wang, Geng 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04 bioresorbable scaffold  first-in-man  intravascular ultrasound  NeoVas  optical coherence tomography  sirolimus